Beijing Biaiou Technology Development Co Ltd

To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of multiple doses of a novel integrated interferon mutant injection of polyethylene glycol in healthy adult subjects and patients with chronic hepatitis B, and to provide a theoretical basis for the dosing regimen of subsequent clinical trials.

To evaluate the safety, tolerability, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of a single dose of a novel integrated interferon mutant injection containing polyethylene glycol in healthy adult subjects, and to provide a theoretical basis for the dosing regimen of subsequent clinical trials.

1. Evaluate the tolerance of multiple doses of PEG-IIFNm in patients with chronic hepatitis B 2. Preliminary observation of the clinical efficacy of PEG-IIFNm on chronic hepatitis B, and provide experimental basis for subsequent clinical research